Introduction: In 5%–10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%–10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs may be an alternative for these patients, although it is not reimbursed for this indication in many countries. Methods: We systematically searched PubMed, Web of Science, and Scopus for reports of anti-IL-1 treatment in FMF patients. Results: Out of 284 potentially relevant articles, 27 eligible reports were identified and included in the data analysis. Conclusion: A complete response to therapy without a single attack during treatment was reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canakinumab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine.
展开▼
机译：简介：在5％–10％的家族性地中海热（FMF）患者中，秋水仙碱不能有效预防发炎。另有5％–10％的患者对有效剂量的秋水仙碱不耐受，并出现严重的副作用。尽管许多国家并未针对这种适应症进行补偿，但抗白细胞介素-1（IL-1）药物的治疗可能是这些患者的替代选择。方法：我们系统地搜索了PubMed，Web of Science和Scopus，以获得FMF患者抗IL-1治疗的报道。结果：在284篇可能相关的文章中，鉴定出27篇合格报告，并将其纳入数据分析。结论：anakinra治疗的患者中有76.5％的患者接受了完全疗法的治疗，而canakinumab治疗期间的患者中有67.5％的患者对治疗的反应完全。在患有AA型淀粉样变性病的患者中，抗IL-1治疗可逆转蛋白尿。对于没有反应或不能耐受秋水仙碱的FMF患者，抗IL-1治疗似乎是一种安全有效的替代方法。
展开▼
